Corcept's Q4 Earnings and Revenues Fall Short of Estimates

Core Insights - Corcept Therapeutics (CORT) reported Q4 2025 earnings of 20 cents per share, missing the Zacks Consensus Estimate of 27 cents, and down from 26 cents per share in the same quarter last year [1][6] - Revenues for Q4 increased by approximately 11.1% year over year to $202.1 million, but fell short of the Zacks Consensus Estimate of $254 million, with the revenue solely coming from product sales of the Cushing's syndrome drug, Korlym [1][3][6] - For the full year 2025, Corcept generated revenues of $761.4 million, an increase from $675 million in the previous year, but earnings per share decreased to 82 cents from $1.23 [7] Financial Performance - Q4 revenues from Korlym missed the model estimate of $250 million [3] - Research and development expenses decreased by 7.7% year over year to $64.9 million, while selling, general, and administrative expenses rose by approximately 56.1% year over year to $130.2 million [3] - Operating expenses increased by 26.2% year over year to $197.6 million in Q4 [3] - Cash and investments as of December 31, 2025, totaled $532.4 million, up from $524.2 million as of September 30, 2025 [3] Future Guidance - Corcept expects total revenues in the range of $900 million to $1 billion for 2026, with the Zacks Consensus Estimate at $1.03 billion [8] Pipeline Developments - Corcept is developing its lead pipeline candidate, relacorilant, for treating Cushing's syndrome and certain cancer indications, with an FDA decision on relacorilant in ovarian cancer expected in July 2026 [9][10] - The company received a complete response letter (CRL) from the FDA for relacorilant in Cushing's syndrome and is currently engaging with the FDA for next steps [11][12] - Corcept is also developing other pipeline candidates, including dazucorilant and miricorilant, for various conditions, with data readouts expected by the end of 2026 [14] Legal and Competitive Landscape - A recent ruling by the United States Court of Appeals upheld that Teva Pharmaceuticals' sale of a generic version of Korlym does not violate Corcept's patents [13] - Corcept currently holds a Zacks Rank of 4 (Sell), while competitors like Harmony Biosciences and Castle Biosciences have better rankings [15]